Charles River Laboratories International has completed the acquisition of a provider of cGMP-compliant contract microbial identification testing services, Accugenix, for $17m in cash.
The acquisition will enable Charles River to expand its Endotoxin and Microbial Detection portfolio of products and services by providing clients with microbial detection services for manufacturing in the medical device, biopharmaceutical, nutraceutical and consumer care industries.
Accugenix is involved in identifying species-level and strain typing of bacteria and fungi that are recovered from manufacturing facilities.
In addition, by utilizing Accugenix’s proprietary in vitro technologies, it will provide accurate, time-effective and cost-effective microbial identification services required to meet internal quality standards and government regulations.
Charles River chairman, president and chief executive officer James Foster said the acquisition of Accugenix has enabled the company to provide rapid microbial and endotoxin detection products and services to the biopharmaceutical industry.
"Over the next several years, we intend to enhance our capabilities through both product extensions and acquisitions," Foster added.
"We believe that execution of this strategy will advance our position as the market leader in endotoxin and microbial detection."